💊 Get Daily Updates on Generic Entry, Litigation, Biosimilars, and More…
Profile for Acceleron Pharma Inc. (XLRN)
« Back to company indexXLRN Chatter Timeline
Stock Ticker for XLRN
Most Active Tweeters for XLRN
| User | Tweets |
|---|---|
| @newsfilterio | 3 |
| @fintel_io | 2 |
| @FlashAlert_me | 2 |
| @AlertTrade | 2 |
| @Biotech2050 | 2 |
Recent Tweets for XLRN
 |
@SweepCastApp SweepCast observed: $XLRN with Unusual Options Activity Alerted on $140 CALL Expiring: 06-18-2021 worth 237K? |? Se… https://t.co/NvQg0UFFWo April 19th 2021, 6:04pm |
|
@SweepCastApp SweepCast observed: $XLRN with Unusual Options Activity Alerted on $140 CALL Expiring: 06-18-2021 worth 237K? |? Se… https://t.co/5l3XiBMaWi April 18th 2021, 6:04pm |
 |
@MarketChmln $XLRN option volume was 15X normal on Friday with 2,255 contracts. Call volume was 55% and put volume was 45%. https://t.co/Sh2bIZBdee April 17th 2021, 5:04pm |
 |
@WALLSTREETODDS_ $XLRN Out of the 986 other times XLRN was down 1.9% during a trading day, 56% of the time it traded higher by the… https://t.co/rRH44OmVzd April 10th 2021, 1:04am |
 |
@deus_trader Optimus v4 2021-04-08 13:35 ET. Bought/Opened: $XLRN at $128.71. Acceleron Pharma, Inc (CORP). Win Chance: 71%. Av… https://t.co/Umh8osO0se April 8th 2021, 5:04pm |
 |
@AlertTrade RT @AlertTrade: REVERSALtoDOWN: $XLRN Acceleron Pharma, Inc https://t.co/vavn4UHszX ? ? TradeIdeas via ? https://t.co/VS8RO1bzXJ April 8th 2021, 4:04pm |
|
@AlertTrade REVERSALtoDOWN: $XLRN Acceleron Pharma, Inc https://t.co/vavn4UHszX ? ? TradeIdeas via ? https://t.co/VS8RO1bzXJ April 8th 2021, 3:04pm |
 |
@bearcapital1 $XLRN I give this company no respect but prob the most consistent bio I follow in regards to execution. When I look… https://t.co/rfMCtz6bJ2 April 8th 2021, 12:04pm |
 |
@MarcJacksonLA $XLRN Acceleron Updates Phase 2 Sotatercept In Treating PAH Set For ATS 2021 https://t.co/pqh3LMfL49 April 7th 2021, 1:04pm |
 |
@YuZhu4 RT @Quantumup1: Credit Suisse $XLRN blue sky valuation of $250 is based on (1) a 90% probability of success for luspatercept in myelofibro… April 6th 2021, 6:04pm |
 |
@maxm_profit RT @SeekingAlpha: $XLRN - Acceleron: Neutral On Stock Price Gains. https://t.co/rb9i7XfSVw #markets #business #stockmarket April 6th 2021, 6:04pm |
 |
@insidersanalyt1 on 2021-04-05 $XLRN insiders' SOLD 21864 securities equal to 0.0361% of outstanding shares. #finance #trading… https://t.co/h2BUGLxN5s April 6th 2021, 6:04pm |
 |
@Biotech2050 RT @semodough: JP $XLRN believe data continue to underscore the differentiated clinical potential of sotatercept for PAH, offering added mo… April 6th 2021, 4:04pm |
 |
@semodough JP $XLRN believe data continue to underscore the differentiated clinical potential of sotatercept for PAH, offering… https://t.co/dQ0NChK4WX April 6th 2021, 4:04pm |
 |
@InsiderAlerts4U $XLRN: New Insider Filing on ACCELERON PHARMA INC's Director KAREN L. SMITH: https://t.co/MJasGOc7SM April 6th 2021, 8:04am |
 |
@newsfilterio $1,299,751.64 of shares sold by Smith Karen L. (Director), reported in a new form 4 filed with the SEC $XLRN https://t.co/b2KTbQIlth April 6th 2021, 5:04am |
|
@newsfilterio $1,166,243.44 of shares sold by Zakrzewski Joseph S (Director), reported in a new form 4 filed with the SEC $XLRN https://t.co/07kcaOLqNh April 6th 2021, 5:04am |
|
@newsfilterio Acceleron: Neutral On Stock Price Gains $XLRN https://t.co/rOFJ0gCnvc April 6th 2021, 3:04am |
|
@Biotech2050 CS - $XLRN Updates from Sotatercept PULSAR and SPECTRA ATS Abstracts (Outperform PT raised to $151) #ATS21… https://t.co/WsA3suODLc April 6th 2021, 3:04am |
 |
@StckPro $XLRN NEW ARTICLE : Acceleron: Neutral On Stock Price Gains https://t.co/g2l3A8w87G Get all the latest $XLRN relate… https://t.co/ZHolChK45X April 6th 2021, 1:04am |
 |
@SeekingAlpha $XLRN - Acceleron: Neutral On Stock Price Gains. https://t.co/rb9i7XfSVw #markets #business #stockmarket April 6th 2021, 1:04am |
 |
@FlashAlert_me $XLRN [15s. delayed] filed SEC form 4: Director Zakrzewski Joseph S: Disposed 10,000 of Common Stock at average pr… https://t.co/cWwQ68R8p7 April 6th 2021, 12:04am |
 |
@fintel_io Insider Joseph S Zakrzewski reports selling 10,000 shares of $XLRN for a total cost of $1,407,343.44 https://t.co/Tq3qGBW5Z8 April 6th 2021, 12:04am |
 |
@formwhisperscom #FWSells $XLRN Smith Karen L., Director of ACCELERON PHARMA INC sold 11,864 shares on 2021-04-05. https://t.co/CXJ6yLgXfc April 6th 2021, 12:04am |
|
@FlashAlert_me $XLRN [15s. delayed] filed SEC form 4: Director Smith Karen L.: Disposed 11,864 of Common Stock at average price $… https://t.co/vZuk1nAIOm April 6th 2021, 12:04am |
|
@fintel_io Insider Smith Karen L. reports selling 11,864 shares of $XLRN for a total cost of $1,663,156.14 https://t.co/b8rIFxMb7Z April 6th 2021, 12:04am |
 |
@Quantumup1 Credit Suisse $XLRN blue sky valuation of $250 is based on (1) a 90% probability of success for luspatercept in my… https://t.co/49GbwXWPg4 April 5th 2021, 10:04pm |
|
@MarcJacksonLA $XLRN HC Wainwright Maintains Buy Rating On Acceleron Pharma, $168 PT https://t.co/Y7I3w8oVeE April 5th 2021, 8:04pm |
|
@MarcJacksonLA $XLRN Acceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hy… https://t.co/VxDV57YLrz April 5th 2021, 2:04pm |
 |
@Briefingcom $XLRN: Acceleron Pharma announced that updates from the PULSAR and SPECTRA Phase 2 clinical trials of sotatercept i… https://t.co/mD3zKs6ZRP April 5th 2021, 1:04pm |
|
@Biotech2050 $XLRN abstracts https://t.co/e9tzjSnQsr April 5th 2021, 12:04pm |
 |
@PCCSMChiefs RT @AcceleronPharma: $XLRN announces updates from the PULSAR and SPECTRA Ph. 2 clinical trials of an investigational agent in #PAH that wil… April 5th 2021, 12:04pm |
 |
@EdgarInsider FORM 8-K [Press/News Current Report] recently SEC filed. $XLRN ACCELERON PHARMA INC https://t.co/xnO3NVckQz April 5th 2021, 11:04am |
|
@fintel_io $XLRN / Acceleron Pharma files form 8-K - Financial Statements and Exhibits - 8-K https://t.co/VfqOU0xVtG April 5th 2021, 11:04am |
 |
@AcceleronPharma $XLRN announces updates from the PULSAR and SPECTRA Ph. 2 clinical trials of an investigational agent in #PAH that… https://t.co/nf5SJSC0Aa April 5th 2021, 11:04am |
 |
@BIOTECH888 RT @MSollender: $XLRN PULSAR and SPECTRA abstracts: https://t.co/FxFSe3h4ef https://t.co/lw1heObADp April 5th 2021, 11:04am |
 |
@MSollender $XLRN PULSAR and SPECTRA abstracts: https://t.co/FxFSe3h4ef https://t.co/lw1heObADp April 5th 2021, 11:04am |
 |
@stock_titan $XLRN Acceleron Announces Clinical Trial Updates, Preclinical Presentations on Sotatercept in Pulmonary Arterial Hy… https://t.co/vM3bNAJk6v April 5th 2021, 11:04am |
 |
@insiderbuyings $XLRN new insider selling: 10000 shares. https://t.co/Ca3gOE5sTn April 3rd 2021, 7:04am |
|
@formwhisperscom #FWSells $XLRN Smith Karen L., Director of ACCELERON PHARMA INC sold 8,925 shares on 2021-04-01. https://t.co/CXJ6yLgXfc April 3rd 2021, 3:04am |
|
@fintel_io Insider Joseph S Zakrzewski reports selling 10,000 shares of $XLRN for a total cost of $1,346,382.36 https://t.co/Tq3qGBW5Z8 April 2nd 2021, 10:04pm |
|
@newsfilterio $1,105,282.36 of shares sold by Zakrzewski Joseph S (Director), reported in a new form 4 filed with the SEC $XLRN https://t.co/GVSFelKV5m April 2nd 2021, 10:04pm |
|
@fintel_io Insider Smith Karen L. reports selling 8,925 shares of $XLRN for a total cost of $1,218,002.72 https://t.co/b8rIFxMb7Z April 2nd 2021, 10:04pm |
|
@newsfilterio $854,598.22 of shares sold by Smith Karen L. (Director), reported in a new form 4 filed with the SEC $XLRN https://t.co/YI7dZ5gW34 April 2nd 2021, 10:04pm |
|
@MarcJacksonLA $XLRN New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with… https://t.co/8Q3IRKOKHC April 1st 2021, 2:04pm |
|
@Briefingcom $XLRN: Acceleron Pharma announced the NEJM has published PULSAR Phase 2 trial results https://t.co/rzHbBvYwia April 1st 2021, 1:04pm |
|
@StckPro $XLRN NEW ARTICLE : New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in… https://t.co/dOYBKvSOZB April 1st 2021, 11:04am |
 |
@sbwcws Acceleron says NEJM publishes results of Pulsar Phase 2 trial of sotatercept $XLRN April 1st 2021, 11:04am |
|
@FlashAlert_me $XLRN [15s. delayed]: Issued Press Release on April 01, 07:00:00: New England Journal of Medicine Publishes Results… https://t.co/NBLqbCwsI2 April 1st 2021, 11:04am |
|
@stock_titan $XLRN New England Journal of Medicine Publishes Results of the PULSAR Phase 2 Trial of Sotatercept in Patients with… https://t.co/ErE9EXCGZm April 1st 2021, 11:04am |
DrugPatentWatch - Make Better Decisions
Contact © thinkBiotech LLC
2004 - 2021. All rights reserved.
Get the DrugPatentWatch Daily Briefing
Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …
Want insights into the biggest revenue-changing events?
Billions of dollars in sales can evaporate overnight as drug patents expire and competitors enter the market.
By tracking patent expirations, patent litigation, generic and biosimilar development, you can anticipate these market-shaping forces and stay one step ahead.
➤ Free Trial
